BCRX (BioCryst Pharmaceuticals) EBIT per Share: $-1.43 (TTM As of Mar. 2026)

What is BioCryst Pharmaceuticals EBIT per Share?

BioCryst Pharmaceuticals BCRX +1.97% 66 EBIT per Share is $-1.43 as of Mar. 2026. GuruFocus rates BCRX with a GF Score™ of 66/100 and a GF Value™ of $12.64 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 811 Drug Manufacturers companies, BioCryst Pharmaceuticals ranks worse than 123304.44% on this metric.

BioCryst Pharmaceuticals's EBIT per Share for the three months ended in Mar. 2026 was $-2.89. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.43.

During the past 12 months, the average EBIT per Share Growth Rate of BioCryst Pharmaceuticals was -1022.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for BioCryst Pharmaceuticals's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of BioCryst Pharmaceuticals was 77.00% per year. The lowest was -53.50% per year. And the median was 1.95% per year.

BCRX's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

BioCryst Pharmaceuticals's EBIT for the three months ended in Mar. 2026 was $-701.0 Mil.

BioCryst Pharmaceuticals (NAS:BCRX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

BioCryst Pharmaceuticals EBIT per Share Related Terms

BioCryst Pharmaceuticals EBIT per Share Historical Data

* Premium members only.

The historical data trend for BioCryst Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals EBIT per Share Chart

BioCryst Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT per Share

Get a 7-Day Free Trial

-0.68

-0.78

-0.61

0.06

1.58

BioCryst Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT per Share	Get a 7-Day Free Trial															0.11	0.13	0.15	1.20	-2.89

66GF Score

BioCryst Pharmaceuticals Inc BCRX

EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioCryst Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

BioCryst Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

	EBIT per Share		(A: Dec. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	346.263	/	218.581
=	1.58

BioCryst Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

	EBIT per Share		(Q: Mar. 2026 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-701.029	/	242.258
=	-2.89

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.43

Frequently Asked Questions Learn more about EBIT per Share →

What does a EBIT per Share of $-1.43 mean?

BioCryst Pharmaceuticals (BCRX) has a EBIT per Share of $-1.43 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioCryst Pharmaceuticals and its competitors. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 811 companies in the Drug Manufacturers industry.

Is BioCryst Pharmaceuticals' EBIT per Share too high?

BioCryst Pharmaceuticals' current EBIT per Share is $-1.43. Based on the distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does BioCryst Pharmaceuticals' EBIT per Share compare to SUPN and PBH?

According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 811 companies for EBIT per Share. This places BioCryst Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT per Share for a Drug Manufacturers company?

The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT per Share mean?

A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioCryst Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCryst Pharmaceuticals's current EBIT per Share is $-1.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioCryst Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.64, compared to a current price of $9.84 — trading 22.2% below its estimated fair value. The current EBIT per Share is $-1.43. BioCryst Pharmaceuticals' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT per Share calculated?

EBIT per Share is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current EBIT per Share is $-1.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?

Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued. The current stock price of $9.84 is trading 22.2% below its estimated GF Value™ of $12.64. GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BCRX:

EBIT per Share: $-1.43
GF Value™: $12.64 vs. price of $9.84 (22.2% below fair value)
GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioCryst Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies SUPN PBH AMLX RGC ANIP TRLV HROW PRGO XERS PAHC XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges BCRX:Mexico BO1:Germany

Address 4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website https://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

66GF Score

Get the complete analysis for BCRX

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.84

Price

$12.64

GF Value

View BCRX Analysis

See EBIT per Share data for all stocks →